Lite Strategy, Inc. (LITS)
0.994
+0.01
(+0.86%)
USD |
NASDAQ |
Sep 01, 16:00
0.9927
0.00 (0.00%)
After-Hours: 20:00
Lite Strategy Research and Development Expense (Annual) : 3.923M for June 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2025 | 3.923M |
| June 30, 2024 | 16.56M |
| June 30, 2023 | 49.65M |
| June 30, 2022 | 85.64M |
| June 30, 2021 | 69.40M |
| June 30, 2020 | 34.06M |
| June 30, 2019 | 32.30M |
| June 30, 2018 | 17.04M |
| June 30, 2017 | 7.237M |
| June 30, 2016 | 13.40M |
| June 30, 2015 | 23.82M |
| June 30, 2014 | 19.33M |
| Date | Value |
|---|---|
| June 30, 2013 | 6.084M |
| June 30, 2012 | 4.915M |
| June 30, 2011 | 2.115M |
| June 30, 2010 | 4.031M |
| June 30, 2009 | 7.777M |
| June 30, 2008 | 9.325M |
| June 30, 2007 | 5.761M |
| June 30, 2006 | 3.427M |
| June 30, 2005 | 2.279M |
| June 30, 2004 | 2.381M |
| June 30, 2003 | 2.024M |
| June 30, 2002 | 0.069M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| SELLAS Life Sciences Group, Inc. | 16.02M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |